- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01163071
A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
November 13, 2019 updated by: Celgene
A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor malignancies and lymphomas.
Study Overview
Detailed Description
Dose limiting toxicities (DLT), maximum tolerated dose (MTD)
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Center Institute
-
-
Texas
-
San Antonio, Texas, United States, 78229
- CTRC @ The Utah Health Science Center @ San Antonio
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be equal or greater 18 years of age
- ECOG performance status less than or equal to 2 (Appendix 2)
- Pts. must be willing and able to sign informed consent
- Cytologically or histologically confirmed solid tumor malignancy or lymphoma for which no standard approved therapy is available. Patients should have accessible tumor lesions amendable to 2 serial biopsies which would not put the patient or their treatment at risk
- Pt. agrees and is willing to provide 2 serial tumor biopsies(optional on first phase, mandatory on 2nd phase)
- During the dose escalation phase, measurable or non-measurable disease as defined by RECIST criteria. At 2nd phase, only patients with measurable disease
- Life expectancy of equal or greater than 12 weeks
- All AEs of any prior chemotherapy, surgery or radiotherapy, must have resolved to grade equal to or less than 1
The following laboratory results must be present within 14 days of initial ABI-011 administration
- Hemoglobin greater or equal to 9g/dL
- Absolute neutrophils count(ANC)greater or equal to 1.5 x 10^9/L
- Platelet count is greater or equal to 100 x 10^9/L
- Serum bilirubin less than or equal to 1.5 x upper limit of normal (ULN)
- Aspartate transaminase (AST) and alanine transaminase (ALT)is less than or equal to 2.5 ULN(except if liver metastases are present; then values must be less than or equal to 5 x ULN)
- Potassium, corrected calcium and magnesium WNL
- Serum Creatinine less than or equal to 1.5 x ULN
- Activated aPTT,PT,INR,WNL
- WNL levels : Troponin I and T, CK-MB,BNP
At least one measurable lesion should be evaluable (DCE-MRI eligibility criteria)and meet at least one of the criteria below:
- At least one measurable lesions should be at least 3 cm in diameter and should not be near the diaphragm or mediastinum
- Lesions should be solid masses that enhance with contrast, without signs of calcification on the most recent computed tomography (CT) or magnetic resonance (MRI)scan
- Pts. must be willing to practice contraceptive methods for the duration of the study and for one month following study completion. Female patients must be postmenopausal, surgically sterile or they must agree to use acceptable methods of birth control. Male patients must be surgically sterile or agree to use an acceptable method of contraception.
- Women of childbearing potential must have a negative serum pregnancy test(B-hCG)within 72 hours prior to first study drug administration
Exclusion Criteria:
- Inability to comply with study and follow-up procedures
- Women who are pregnant or lactating
- Treatment with chemotherapy, hormonal therapy(except leuprolide for prostate cancer), immunotherapy, biologic therapy, or radiation therapy as cancer therapy within 4 weeks before initiation of study treatment. Six weeks should have elapsed if prior chemotherapy treatment included nitrosoureas or mitomycin C
- Pts. who have received antibody-based therapies within 28 days or 5 half-lives of the agent, whichever time period is longer
- Major surgery within 6 weeks before first study drug administration
- Prior treatment with tumor vascular disruptive agents
- Any uncontrolled medical or psychiatric risk factors
- Central nervous system(CNS)metastases.
- History of diabetic retinopathy. All patients must be evaluated by an ophthalmologist prior to study treatment
- Any history of myopathy, either peripheral or cardiac
- Current use of medications that may have the potential of QTc prolongation
- History of allergy or hypersensitivity to any compound of the ABI-011 formulation
- Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy
- Pt.has known infection with human immunodeficiency virus (HIV),or known chronic Hepatitis B or Hepatitis C
- Inability to be venipunctured and/or tolerate venous access
- History of other carcinoma within past 5 years
- Pts. requiring therapeutic anticoagulation with either coumadin or low molecular weight heparin or with history of any bleeding diathesis. Low dose aspirin and low dose coumadin for catheter maintenance are allowed
- Lung tumors in a central position.
Cardiac exclusion criteria:
- Left ventricular ejection fraction (LVEF)< 50% by echocardiography;
- Previous history of MI or ischemic heart disease
- EKG findings suggestive of current or previous ischemic heart disease, including left bundle branch block
- Prior treatment with chemotherapy agents known to potentially cause cardiotoxicity
- Class III or IV heart failure as defined by the New York Heart(NYHA) functional classification
- Congenital or acquired long QT syndrome
- Uncontrolled hypertension
- Current or past history of clinically significant arrhythmias
- QTc prolongation
- HO Symptomatic PVD (Venous or arterial)
- Seizure disease requiring current anticonvulsant treatment
- HO previous CVA or TIA
- HO inflammatory bowel disease (active or past) or active PUD
- HO previous, whole abdomen radiation therapy or more than Grade 1 residual toxicity from previous radiation therapy.
- History of autoimmune disease or vascular disease (venous or arterial)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ABI-011
|
ABI-011
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DLT's and MTD Safety and Toxicity profile
Time Frame: During Cycle 1, treatment period, End of Study and Follow-Up, approximately up to 2 years
|
Evaluate PK and PD of ABI-011.
Preliminary assessment of tumor response.
|
During Cycle 1, treatment period, End of Study and Follow-Up, approximately up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and toxicity profile of repeated dosing of ABI-011
Time Frame: End of study and follow up, approximately up to 2 years
|
Number of subjects with Adverse Events; laboratory assessments, ECG assessments, opthalmologic assessments
|
End of study and follow up, approximately up to 2 years
|
Evaluate plasma PK of ABI-011 on this schedule
Time Frame: End of Study and follow-up, Up to two years
|
End of Study and follow-up, Up to two years
|
|
Assess biological activity and PD of ABI-011
Time Frame: End of study and follow-up, approximately 2 years
|
End of study and follow-up, approximately 2 years
|
|
Make preliminary assessment of tumor response
Time Frame: End of study and follow-up, approximately 2 years
|
End of study and follow-up, approximately 2 years
|
|
Assess biological activity/exploratory during treatment C1, C2, EOS
Time Frame: End of Study and follow-up, aproximately two years
|
End of Study and follow-up, aproximately two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Patricia M LoRusso, DO, Karmanos Cancer Institute Hudson-Webber Cancer Research Center
- Principal Investigator: John Sarantopoulos, MD, Cancer Therapy Research Center at the University Health Sciences Center at San Antonio
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2011
Primary Completion (Actual)
September 23, 2011
Study Completion (Actual)
September 23, 2011
Study Registration Dates
First Submitted
June 15, 2010
First Submitted That Met QC Criteria
July 14, 2010
First Posted (Estimate)
July 15, 2010
Study Record Updates
Last Update Posted (Actual)
November 14, 2019
Last Update Submitted That Met QC Criteria
November 13, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA601
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
Clinical Trials on ABI-011
-
NantBioScience, Inc.WithdrawnNeoplastic DiseaseUnited States
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
Nexel Co., Ltd.Novotech (Australia) Pty LimitedCompleted
-
AbbVieCompletedSmall Cell Lung CancerUnited States, Japan, Korea, Republic of, Taiwan
-
Hutchison Medipharma LimitedCompletedInflammatory Bowel Diseases
-
Assembly BiosciencesCompletedChronic Hepatitis BNew Zealand
-
Assembly BiosciencesCompletedChronic Hepatitis BKorea, Republic of, Australia, United States, Hong Kong, United Kingdom, China, New Zealand
-
Orionis Biosciences IncRecruiting
-
Aura BiosciencesRecruitingMuscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaAnemia | Myelofibrosis | Myelodysplastic/Myeloproliferative NeoplasmUnited States